Enregistrement :
19
de
40
(2017-09-16
à
2018-04-17)
Politique ou Programme
Canada's Innovation Agenda: ensuring that the life sciences industry is included and promoting awareness of and support for the full ecosystem from early stage research to commercialization and reimbursement.
Input into the Patented Medicines Price Review Board evaluation of annual Research and Development investments by companies in Canada based on SR&ED tax rules. Working with PMPRB and legislators to ensure appropriate measures of R&D investment are in place.
Politique ou Programme, Proposition législative, Projet de loi ou résolution
The House of Commons Standing Committee on Health's (HESA) and the Standing Committee on Social Affairs review of the 2004-2014 Health Accord and renegotiation of the 2014 Health Accord
Politique ou Programme, Proposition législative, Projet de loi ou résolution, Règlement
Research and Development: Input on Canada's clinical trial approval and implementations processes; Investing in Canada in R&D
Politique ou Programme, Règlement
Health Canada PMPRB proposed regulation changes are the regulatiuons
Health Canada consulted on Proposed Amendments to the Patented Medicines Regulations. Discussions on changing the basket of comparative countries and its unintended economic consequences in Canada. In particular its impact on the Life Sciences Sector and wait times for medicines for Canadians
Title: “Protecting Canadians from Excessive Drug Prices: Consulting on Proposed Amendments to the Patented Medicines Regulations”
Proposition législative, Projet de loi ou résolution
Comprehensive Economic Trade Agreement with Europe (CETA) and pharmaceutical intellectual property protection.
Health Canada's enforcement of Canada's Food and Drugs Act and Regulations as they relate to the cross border sale of drugs to the United States.
Règlement
An amendment to the Patented Medicines (Notice of Compliance) Regulations ("PM(NOC) Regulations") regarding the right to appeal.
Health Canada's proposal to add the drug tramadol to the Schedule of the Narcotic Control Regulations (NCR) with regard to changing the status of this prescription product to a controlled substance and the scheduling process for new products
Modernization of Food & Drug Act: support for proposed regulatory changes, modernization and international harmonizations with other regulatory bodies (EMA/FDA).
Subsequent Entry Biologics (SEBs): the need for regulatory amendments to facilitate their approval.